A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed Dyslipidemia
Sponsor: Eli Lilly and Company
This PHASE2 trial investigates Dyslipidemias and Hyperlipoproteinemia and is currently completed. Eli Lilly and Company leads this study, which shows 21 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
21 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 16 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .